Imprimis Pharmaceuticals Inc (IMMY)

[MasterBidder]

BK case dismissed bodes very well for equity's survival - refer to Pacer.

As for the Status of Ketotransdel and their other products:

Ketotransdel - Completed a Phase 3 trial in 2009 and reported that the Ketotransdel study demonstrated statistical significance in its primary endpoint in the modified Intent-To Treat (ITT) Analysis. Ketotransdel also demonstrated an excellent safety and tolerability profile. Based on discussions with the FDA at least two adequate and well-controlled Phase 3 studies are required in order to obtain regulatory approval to market Ketotransdel. We believe that the first Phase 3 trial will qualify as one adequate and well-controlled trial because there is statistical significance on the primary endpoint in an objectively defined modified ITT population, and statistical significance on secondary endpoints. We are in the process of determining the design of the second Phase 3 trial. There is no assurance that the FDA will accept our conclusion of the modified ITT data from the first Phase 3 study as sufficient as part of the requirements for regulatory approval. Cosmeceutical Anti-Cellulite product - We have entered into a license agreement with JH Direct, LLC ("JH Direct") providing JH Direct with the exclusive worldwide rights to our anti-cellulite cosmeceutical product. Under the terms of the agreement, JH Direct will pay us initial royalty advances if the product is marketed and a continuing licensing royalty on the worldwide sales of the anti-cellulite product. We anticipate that JH Direct will launch the anti-cellulite product through a direct response television campaign during the second half of 2010. As part of the JH Direct agreement, Transdel retained the exclusive rights to seek dermatological partners for the anti-cellulite product for an initial period of one year following the launch of the product, thereafter JH Direct will be allowed to expand in this channel. In June 2010, we out-licensed the exclusive U.S. rights for the anti-cellulite product in the dermatological markt product to Jan Marini Skin Research, Inc.

http://www.onemedplace.com/database/list/cid/13943/